Reference List of Excluded Studies for Clinical Question 2 (contacts) and reason for exclusion

   Ref ID: 6130

**EXC-Review article**

   Ref ID: 1812

**EXC-PPD based IGRA**

   Ref ID: 96

**EXC-Non-commercial IGRA used (antigens not specified)**

   Ref ID: 709

**EXC-Not contact investigation**

   Ref ID: 22

**EXC-Not focused on Latent TB Infection (definition of LTBI not adequate)**

   Ref ID: 3420

**EXC-Majority of new Health Care Workers had no risk factors for TB**

   Ref ID: 2170

**EXC-Not focused on diagnosis of LTBI**

   Ref ID: 48

**EXC-Focuses on reproducibility of IGRA**
Ref ID: 515

**EXC-Not focused on LTBI**

Ref ID: 1619

**EXC-To be addressed in question focusing on children**

Ref ID: 170

**EXC-Used TST only**

Ref ID: 792

**EXC-Not contact tracing (no gradient of exposure to TB)**

Ref ID: 491

**EXC-TST only (no IGRA)**

Ref ID: 1975

**EXC-Editorial**

Ref ID: 849

**EXC-To be addressed in question focussing on children**

Ref ID: 164

**EXC-To be addressed in question focussing on children**

Ref ID: 3967

**EXC-Screening not contact (only one had contact with TB patient)**

Ref ID: 1049
EXC-PPD based IGRA


EXC-Not focused on diagnosis of Latent TB Infection (focus on inactive and active TB)


EXC-PPD based IGRA


EXC-No gradient of exposure to TB


EXC-To be addressed in question focussing on children


EXC-To be addressed in question focussing on children


EXC-PPD based Quantiferon


EXC-No grading of exposure to TB


EXC-PPD based IGRA


EXC-Focus on test after treatment


TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 3 of 30
increase acceptance of preventive therapy for latent tuberculosis among healthcare workers? *Infection Control & Hospital Epidemiology*, 30, (2) 197-199
Ref ID: 257

**EXC-Focuses on treatment**

Ref ID: 3444

**EXC-TST taken from medical history (time between tests too long).**

Ref ID: 2127

**EXC-Only TST used (no IGRA)**

Ref ID: 3725

**EXC-Non-commercial IGRA (antigens not specified)**

Ref ID: 734

**EXC-No grading of exposure to TB**

Ref ID: 6228

**EXC-No TST used as a comparator**

Ref ID: 202

**EXC-No gradient of exposure**

Ref ID: 1828

**EXC-PPD based IGRA**

Ref ID: 2

**EXC-Focuses on reproducibility of IGRA**
Ref ID: 3

**EXC-TST taken from medical history (time between tests too long).**

Ref ID: 3406

**EXC-No grading of exposure to TB**

Ref ID: 210

**EXC-No grading of exposure to TB (details of correlations not given)**


**EXC-No grading of exposure to TB**

Ref ID: 560

**EXC-No grading of exposure to TB**


**EXC-Non-commercial IGRA**


**EXC-Non-commercial IGRA**
List of excluded studies for Occupational Health Screening

References

Ref ID: 204

Not screening Healthcare workers

Ref ID: 350

Not screening Healthcare workers

Ref ID: 491

Did not use IGRA

Ref ID: 567

Not a study on screening

Ref ID: 658

Focus on Diagnosis

Ref ID: 680

Not screening

Ref ID: 690

Used IGRA alone

Ref ID: 871

Not a study on Healthcare workers
Ref ID: 1411

**Not a study on Healthcare workers**

Ref ID: 1968

**Study not focused on Latent tb**

---

**Excluded list-CQ4-Immunocompromised**

Ref ID: 17

**EXC-Focus on prevention**

Ref ID: 18

**EXC-Correspondence**

Ref ID: 39

**EXC-to be considered for cost-effectiveness**

Mori, T. 2009. Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. [Review] [106 refs]. *Journal of Infection & Chemotherapy*, 15, (3) 143-155
Ref ID: 65

**EXC-Review**

Ref ID: 71

**EXC-Active TB**

Ref ID: 80

**EXC-LTBI included patients with CXR scar**
Ref ID: 83

**EXC-Diagnosing active TB**

Ref ID: 94

**EXC-Focus on allergic sensitisation**

Ref ID: 103

**EXC-Overview of TB screening in RA patients on biologic therapy**

Ref ID: 121

**EXC-Both active and latent TB**

Ref ID: 123

**EXC-Active TB**

Ref ID: 133

**EXC-Overview of tests**

Ref ID: 140

**EXC-No comparison with TST**

Ref ID: 143

Not accessible

Lalvani, A. & Millington, K.A. 2008. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. [Review] [39 refs]. *Autoimmunity Reviews*, 8, (2) 147-152
Ref ID: 144

**EXC-Review**

Ref ID: 153

**EXC-Review using active TB and low incidence as gold standard**
Lauzardo, M. 2009. Will new TB tests be effective in HIV-infected individuals? *HIV Clinician*, 21, (2) 13-14
Ref ID: 156

**EXC-Discussion**

Bocchino, M., Bellofiore, B., Matarese, A., Galati, D., & Sanduzzi, A. 2009. IFN-gamma release assays in tuberculosis management in selected high-risk populations. [Review] [203 refs]. *Expert Review of Molecular Diagnostics*, 9, (2) 165-177
Ref ID: 166

**EXC-Review article**

Ref ID: 175

**EXC-PPD based study**

Ref ID: 178

**EXC-Indeterminate TST from history**

Ref ID: 184

**EXC-Non-commercial IGRA**

Ref ID: 187

**EXC-Comparing QFT with T-SPOT**

Ref ID: 188

**EXC-Comparing lymphocyte transformation test with TST**

Ref ID: 190

**EXC-Comparing antigens**

Ref ID: 191

**EXC-Editorial**

Pasquinelli, V., Townsend, J.C., Jurado, J.O., Alvarez, I.B., Quiroga, M.F., Barnes, P.F., Samten, B., & Garcia, V.E. 2009. IFN-gamma production during active tuberculosis is regulated by mechanisms that involve IL-17, SLAM, and CREB. *Journal of Infectious Diseases*, 199, (5) 661-665
Ref ID: 212

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 9 of 30
EXC-Focus on transcription propeptides of IGRA

Ref ID: 217

EXC-Not comparing IGRA with TST

Ref ID: 263

EXC-No comparison with TST

Ref ID: 267

EXC-Active TB used as gold standard

Oon, H.H., Chong, W.S., & Liew, C.F. 2008. Indeterminate results on the interferon-gamma release assay for tuberculosis screening should not be ignored. [Comment]. *British Journal of Dermatology, 159*, (4) 992-993
Ref ID: 312

EXC-Correspondence

Ref ID: 351

EXC-Overview of use in children

Ref ID: 364

EXC-Active TB

Ref ID: 392

EXC-Screening algorithm

Manuel, O. & Kumar, D. 2008. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection. [Review] [49 refs]. *Expert Review of Molecular Diagnostics, 8*, (3) 247-256
Ref ID: 400

EXC-Reviews of Quantiferon

Ref ID: 414

EXC-Overview


TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 10 of 30
EXC-Examining whether TST might affect the monitoring of the immune response of vaccine

Ref ID: 451

EXC-PPD based IGRA (1st generation QFT)

Ref ID: 471

EXC-Commentary

Ref ID: 475

EXC-Correspondence

Ref ID: 537

EXC-Case series

Ref ID: 539

EXC-Update

Ref ID: 545

EXC-Screening

Zellweger, J.P. 2008. Latent tuberculosis: which test in which situation?. [Review] [74 refs]. Swiss Medical Weekly, 138, (3-4) 31-37
Ref ID: 551

EXC-Discussion paper

Ref ID: 552

EXC-Using non-commercial novel flow cytometric IGRA

Ref ID: 554

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 11 of 30
EXC-Non-commercial IGRA

Ref ID: 564

EXC-No comparison with TST

Ref ID: 572

EXC-Position statement

Kaushik, V.V., Ambalavanan, S., & Binymin, K. Comment on: Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience.[comment]. *Rheumatology*, 46, (12) 1863-1864
Ref ID: 597

EXC-Comment

Ref ID: 600

EXC-Correspondence

Ref ID: 607

EXC-Non-commercial assay

Ref ID: 622

EXC-Assessing risk factors associated with tests

Ref ID: 631

EXC-Overview of utility of tests

Ref ID: 661

EXC-Policy statement

Ref ID: 668

EXC-No detailed info

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 12 of 30
Ref ID: 685

EXC-Comparison with expert panel

Ref ID: 704

EXC-Comparing BCG patients with non-BCG

Ref ID: 735

EXC-Summary of cases

Pratt, A., Nicholl, K., & Kay, L. 2007. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience.[see comment]. *Rheumatology*, 46, (6) 1035-1036
Ref ID: 749

EXC-Letter

Ref ID: 752

EXC-Overview of research agenda

Wallis, R.S. 2007. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. [Review] [51 refs]. *Journal of Investigative Dermatology*, Symposium, (1) 16-21
Ref ID: 767

EXC-Focus on antigen IP10 and the comparison of reactivation of LTBI with either infliximab or etanercept

Lalvani, A. & Millington, K.A. 2007. T cell-based diagnosis of childhood tuberculosis infection. [Review] [52 refs]. *Current Opinion in Infectious Diseases*, 20, (3) 264-271
Ref ID: 776

EXC-Indeterminate between ELISPOT and T-SPOT

Ref ID: 836

EXC-Comment

Ref ID: 839

EXC-Summary of cases

Ref ID: 848

EXC-Identification of LTBI and care of TB infected cases
Ref ID: 888

EXC-Discussion paper

Ref ID: 947

EXC-Combine active and latent TB

Ref ID: 953

EXC-No comparison with TST

Ref ID: 958

EXC-Letter

Ref ID: 1005

EXC-PPD based IGRA

Ref ID: 1014

EXC-Review article

Ref ID: 1036

EXC-Investigating IFN-gamma secreting capacity

Ref ID: 1081

EXC-Correspondence

Ref ID: 1118

EXC-Research letter

Ref ID: 1217
EXC-Depressive symptoms of LTBI cases

Ref ID: 1234

EXC-Overview of test in different at risk groups

Ref ID: 1305

EXC-Screening update

Ref ID: 1306

EXC-Commentary

Ref ID: 1352

EXC-Comment

Ref ID: 1458

EXC-Investigating PPD reactivity

Ref ID: 1462

EXC-Comment

Coker, R. 2004. Compulsory screening of immigrants for tuberculosis and HIV.[see comment]. BMJ, 328, (7435) 298-300
Ref ID: 1487

EXC-Commentary

Ref ID: 1614

EXC-Review article

Ref ID: 1675

EXC-PPD based IGRA

Ref ID: 1954

EXC-Review

Kimura, M., Converse, P.J., Astemborski, J., Rothel, J.S., Vlahov, D., Comstock, G.W., Graham, N.M., Chaisson, R.E., & Bishai, W.R. 1999. Comparison between a whole blood interferon-gamma release assay and tuberculin skin

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 15 of 30
testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. *Journal of Infectious Diseases*, 179, (5) 1297-1300
Ref ID: 2124

EXC-PPD based IGRA

Ref ID: 2320

EXC-PPD based IGRA/ focus on active TB

Ref ID: 2407

EXC-Letter to editor

Ref ID: 2566

EXC-Control of TB

Ref ID: 2648

EXC-Letters to the editor

Ref ID: 2768

EXC-Guideline

Ref ID: 2800

EXC-Focus on technique for detection of antigens in synovial fluid

Ref ID: 3398

EXC:

Ref ID: 3409

EXC-Case series

Ref ID: 3412

EXC-Case series

Ref ID: 3416
EXC-Case study
Ref ID: 3417

EXC-Differential analysis for TST and IGRA
Ref ID: 3420

EXC-To consider for contacts (screening)
Ref ID: 3422

EXC-Insufficient data analysis
Ref ID: 3431

EXC-Review article
Ref ID: 3442

Inaccessible

Ref ID: 3445

EXC-Correspondence
Ref ID: 3530

EXC-Non commercial IGRA
Ref ID: 3611

Inaccessible

Ref ID: 3718

EXC-Overview

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 17 of 30
Ref ID: 3769

Inaccessible

Ref ID: 3784

EXC-Overview of prospects of new diagnostic tests

Ref ID: 3819

EXC-Comparing QFT with T-SPOT

Ref ID: 3872

EXC-Editorial

Ref ID: 3908

EXC-Overview of risk factors in high burden countries

Ref ID: 3959

EXC-Correspondence

Ref ID: 3964

EXC-Case report

Ref ID: 4063

EXC-Correspondence

Ref ID: 4106

EXC-Evaluating 1st and 2nd generation IGRA

Ref ID: 4176

EXC-Commentary

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 18 of 30
Nelson, K. 2007. Tuberculin testing to detect latent tuberculosis in developing countries. *Epidemiology*, 18, (3) 348-349
Ref ID: 4235

EXC-Commentary

Ref ID: 4290

Inaccessible

Ref ID: 4297

EXC-Overview

Ref ID: 4385

EXC-Examining antibody effects of TNF blocker

Ref ID: 4451

EXC-Commentary

Ref ID: 4452

EXC-Commentary

Ref ID: 4465

EXC-Commentary

Ref ID: 5033

EXC-Commentary

Ref ID: 5351

EXC-Overview of diagnosis

Greveson, K. 2009. Can ELISpot replace the tuberculin skin test for latent tuberculosis? *British Journal of Nursing (BJN)*, 18, (20) 1248-1254 available from:
http://search.ebscohost.com/login.aspx?direct=true&db=c8h&AN=2010470325&site=ehost-live;Publisher URL: www.cinahl.com/cgi-bin/refsvc?jid=596&accno=2010470325
Ref ID: 6134

EXC-Overview
Ref ID: 6202

EXC-Assessing prevalence and HIV as a risk factor for undiagnosed TB

Ref ID: 6282

EXC-Treatment

---

**Reference List of Excluded Studies for Clinical Question 3 (children) and reason for exclusion**

Ref ID: 9

**EXC-Focus on specific biomarker (IP-10)**

Ref ID: 55

**EXC-To be addressed in CQ4**

Ref ID: 63

**EXC-Comparison of active and latent TB**

Ref ID: 73

**EXC-No grading of exposure to TB**

Ref ID: 118

**EXC-Focus on specific biomarker (IP-10)**

EXC-Focus on effect of treatment

Ref ID: 290

EXC-Use ELISPOT as gold standard

Ref ID: 295

EXC-Focus on specific biomarker (IP-10)

Ref ID: 317

EXC-Focus on PPD based IGRA

Ref ID: 324

EXC-Non-commercial IGRA with unknown antigens

Ref ID: 327

EXC-Focus on specific biomarker (IP-10)

Ref ID: 351

EXC-Review article

13) Rothel, J. & Veeser, P.I. Response to "Tuberculosis Screening on a Health Science Campus: Use of QuantiFERON-TB Gold Test for Students and Employees".[comment]. *Journal of American College Health*, 57, (1) 121-124
Ref ID: 376

EXC-Letter

Ref ID: 384

EXC-Focus on boosting of IGRA

15) Etuwewe, O.M. & Riordan, A. 2008. IGRA for children in the UK: patchy availability, problems with funding, lack of clarity about its role.[comment]. *Archives of Disease in Childhood*, 93, (8) 714
Ref ID: 390

EXC-Letter

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 21 of 30
Ref ID: 441

**EXC-Used T-SPOT as a gold standard**

Ref ID: 486

**EXC-To be addressed in CQ4**

18) Shingadia, D. & Novelli, V. 2008. The tuberculin skin test: a hundred, not out?[comment]. *Archives of Disease in Childhood*, 93, (3) 189-190  
Ref ID: 512

**EXC-Review**

Ref ID: 716

**EXC-Insufficient data for analysis**

20) Lalvani, A. & Millington, K.A. 2007. T cell-based diagnosis of childhood tuberculosis infection. [Review] [52 refs]. *Current Opinion in Infectious Diseases*, 20, (3) 264-271  
Ref ID: 776

**EXC-Review article**

21) Ranganathan, S., Connell, T., & Curtis, N. Interferon-gamma release assays in children--no better than tuberculin skin testing?[comment]. *Journal of Infection*, 54, (4) 412-413  
Ref ID: 800

**EXC-Letter to editor**

Ref ID: 824

**EXC-Focus on active TB**

Ref ID: 850

**EXC-Case study**

Ref ID: 913

**EXC-Review article**

Ref ID: 942
EXC-Review

Lancet, 368, (9532) 282-283
Ref ID: 959

EXC-Review

Mycobacterium tuberculosis-specific antigens. Molecular Diagnosis & Therapy, 10, (1) 57-63
Ref ID: 1014

EXC-Focus on active TB

Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The 
Gambia. International Journal of Tuberculosis & Lung Disease, 10, (2) 192-198
Ref ID: 1049

EXC-PPD based IGRA

interferon-based immunodiagnosis of tuberculosis: comparison between whole-blood and enzyme-linked 
immunospot methods. Journal of Clinical Microbiology, 42, (2) 829-831
Ref ID: 1485

EXC-Adult study

Pediatric Infectious Disease Journal, 23, (1) 71-72
Ref ID: 1491

EXC-Review

31) Vekemans, J., Ota, M.O., Sillah, J., Fielding, K., Alderson, M.R., Skeiky, Y.A., Dalemans, W., McAdam, K.P., 
Lienhardt, C., & Marchant, A. 2004. Immune responses to mycobacterial antigens in the Gambian population: 
implications for vaccines and immunodiagnostic test design. Infection & Immunity, 72, (1) 381-388
Ref ID: 1498

EXC-Not focused on diagnosis of LTBI (non-commercial IGRA used)

and treatment. [Review] [28 refs]. Current Women’s Health Reports, 3, (4) 303-308
Ref ID: 1585

EXC-Review

Committee of the British Thoracic Society.[see comment]. [Review] [101 refs]. Thorax, 55, (11) 887-901
Ref ID: 1954

EXC-Guidelines

infection among new school entrants, New York City, 1991-1993.[see comment]. International Journal of 
Tuberculosis & Lung Disease, 3, (1) 31-41
Ref ID: 2127

EXC-TST alone

tuberculosis in children using two ELISA kits. Indian Journal of Pediatrics, 66, (6) 837-842
Ref ID: 2145

EXC-Focus on active TB

TB (partial update) short clinical guideline - Appendices 5 - (July 2010) Page 23 of 30
Ref ID: 2161

**EXC-No IGRA used**

Ref ID: 2353

**EXC-Review**

Ref ID: 2549

**EXC-Editorial**

Ref ID: 3065

**EXC-Review article**

Ref ID: 3431

**EXC-Review article**

41) Sharma, N. 2009. ELISpot as a predictor for development of tb in children with tb contact. Thorax, 64, (4) 320  
Ref ID: 3466

**EXC-Letter**

Ref ID: 3718

**EXC-Review article**

Ref ID: 4264

**EXC-Letter to editor**

Ref ID: 4270

**EXC-No IGRA used**

45) Stark, J.R. 2006. Use of new TB test in children should be limited. Indian Journal of Pediatrics, 73, (5) 422  
Ref ID: 4358

**EXC-Review**

Ref ID: 4740
EXC-Guidelines

Ref ID: 5018

EXC-Review article/ commentary

Ref ID: 6224

EXC-Review article

Ref ID: 6283

EXC-IGRA not used

Ref ID: 500

EXC-No detailed analysis & no grading of exposure to TB

Ref ID: 307

EXC-Focus on active TB

Ref ID: 105

EXC-Assesses treatment effectiveness

Use of IGRA testing in people from high prevalence countries – excluded studies

<table>
<thead>
<tr>
<th>Bibliographic Reference</th>
<th>Title and source</th>
<th>Ref ID</th>
<th>Reason for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bibliographic Reference</td>
<td>Title and source</td>
<td>Ref ID</td>
<td>Reason for Exclusion</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------</td>
<td>--------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Bakhshi, S. 2001</td>
<td>Bakhshi S. Tuberculosis screening of new entrants; how can it be made more effective?[comment]. J PUBLIC HEALTH MED 2001; 23(1):82-83.</td>
<td>1880</td>
<td>Correspondence</td>
</tr>
<tr>
<td>Bibliographic Reference</td>
<td>Title and source</td>
<td>Ref ID</td>
<td>Reason for Exclusion</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------</td>
<td>--------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Ref ID</td>
<td>Reason for Exclusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4620</td>
<td>Not a study on IGRA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1911</td>
<td>Not addressing question 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1972</td>
<td>BMJ Comment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>324</td>
<td>Foreign based study and looking at kids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1491</td>
<td>Concise Review not a study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1138</td>
<td>Not LTBI focused</td>
<td></td>
<td></td>
</tr>
<tr>
<td>307</td>
<td>Children</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1147</td>
<td>QFT IGRA is PPD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>636</td>
<td>Consider for question 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3447</td>
<td>Consider for question 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>250</td>
<td>Question 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2069</td>
<td>IGRA is PPD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibliographic Reference</td>
<td>Title and source</td>
<td>Ref ID</td>
<td>Reason for Exclusion</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------</td>
<td>--------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Shams, H., Weis, S.E., Klucar, P., Lavani, A., Moonan, P.K., Pogoda, J.M., Ewer, K., &amp; Barnes, P.F. 2005</td>
<td>Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. AM J RESPIR CRIT CARE MED 2005; 172(9):1161-1168.</td>
<td>1121</td>
<td>Consider for question 2</td>
</tr>
</tbody>
</table>